California Public Employees Retirement System Sells 4,962 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

California Public Employees Retirement System trimmed its holdings in 10x Genomics, Inc. (NASDAQ:TXGGet Rating) by 3.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 160,300 shares of the company’s stock after selling 4,962 shares during the quarter. California Public Employees Retirement System owned approximately 0.14% of 10x Genomics worth $12,194,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. National Bank of Canada FI bought a new position in shares of 10x Genomics during the 4th quarter valued at approximately $43,000. Janney Montgomery Scott LLC boosted its position in shares of 10x Genomics by 332.0% during the 4th quarter. Janney Montgomery Scott LLC now owns 6,160 shares of the company’s stock valued at $918,000 after acquiring an additional 4,734 shares during the last quarter. National Asset Management Inc. bought a new position in shares of 10x Genomics during the 4th quarter valued at approximately $314,000. Illinois Municipal Retirement Fund boosted its position in shares of 10x Genomics by 40.0% during the 4th quarter. Illinois Municipal Retirement Fund now owns 5,008 shares of the company’s stock valued at $746,000 after acquiring an additional 1,431 shares during the last quarter. Finally, CWM LLC bought a new position in shares of 10x Genomics during the 4th quarter valued at approximately $1,221,000. 76.25% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO Justin J. Mcanear sold 967 shares of the firm’s stock in a transaction on Monday, May 23rd. The stock was sold at an average price of $48.76, for a total transaction of $47,150.92. Following the transaction, the chief financial officer now owns 59,079 shares in the company, valued at $2,880,692.04. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Serge Saxonov sold 2,656 shares of the firm’s stock in a transaction dated Monday, May 23rd. The stock was sold at an average price of $48.76, for a total transaction of $129,506.56. Following the sale, the chief executive officer now owns 968,817 shares of the company’s stock, valued at $47,239,516.92. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Justin J. Mcanear sold 967 shares of the firm’s stock in a transaction dated Monday, May 23rd. The shares were sold at an average price of $48.76, for a total value of $47,150.92. Following the sale, the chief financial officer now directly owns 59,079 shares in the company, valued at approximately $2,880,692.04. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,887 shares of company stock worth $238,290. Company insiders own 11.57% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TXG. Bank of America lowered 10x Genomics from a “neutral” rating to an “underperform” rating and set a $35.00 price target on the stock. in a report on Friday, July 15th. Cowen decreased their price target on 10x Genomics from $90.00 to $50.00 and set an “outperform” rating on the stock in a report on Friday, July 15th. Canaccord Genuity Group began coverage on 10x Genomics in a report on Monday, July 25th. They set a “buy” rating on the stock. Cowen decreased their price target on 10x Genomics from $90.00 to $50.00 in a report on Friday, July 15th. Finally, William Blair lowered 10x Genomics from an “outperform” rating to a “market perform” rating in a report on Friday, July 15th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $72.38.

10x Genomics Stock Up 0.1 %

TXG stock opened at $42.62 on Friday. The business’s fifty day simple moving average is $43.27 and its two-hundred day simple moving average is $60.74. 10x Genomics, Inc. has a twelve month low of $33.30 and a twelve month high of $191.15. The firm has a market cap of $4.81 billion, a price-to-earnings ratio of -53.95 and a beta of 1.66.

10x Genomics (NASDAQ:TXGGet Rating) last released its earnings results on Wednesday, May 4th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). The business had revenue of $114.50 million during the quarter, compared to analysts’ expectations of $113.33 million. 10x Genomics had a negative return on equity of 11.10% and a negative net margin of 17.85%. The business’s revenue for the quarter was up 8.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.11) EPS. Research analysts expect that 10x Genomics, Inc. will post -1.22 EPS for the current year.

10x Genomics Profile

(Get Rating)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Further Reading

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.